Literature DB >> 28659392

Change in vision-related quality of life and influencing factors in Asians receiving treatment for neovascular age-related macular degeneration.

Eva K Fenwick1,2, Gemmy Chui Ming Cheung1,3, Alfred Tl Gan1, Gavin Tan1,3, Shu Yen Lee1,3, Doric Wong1,3, Ian Yeo1,3, Ranjana Mathur1,3, Tien Y Wong1,2,3, Ecosse L Lamoureux1,2,3.   

Abstract

AIM: To assess the change in vision-related quality of life (VRQoL) after treatment for neovascular age-related macular degeneration (nAMD) and factors influencing this change in an Asian population.
METHODS: In this longitudinal study, 116 patients (mean age±SD=66.5±9.9 years; 59.5% male) who underwent treatment for nAMD were recruited from a tertiary eye centre in Singapore. Best-corrected visual acuity (BCVA) and the Impact of Vision Impairment (IVI) questionnaire were evaluated at baseline and month 12. We defined three categories of BCVA change in the treated eye: BCVA gain ≥2 lines; no change in BCVA; BCVA loss ≥2 lines. The main outcome measures were the Rasch-derived IVI Reading, Mobility, and Emotional Scores. Multivariable linear regression analyses assessed the influence of sociodemographic, clinical and treatment-related factors on change in VRQoL.
RESULTS: Following treatment, mean treated-eye BCVA improved by almost 2 lines (-0.22±0.40 logMAR, p<0.001) and 43% (n=50) patients reported a gain in BCVA of ≥2 lines. Mean±SD scores for Reading, Mobility and Emotional demonstrated positive changes of 0.43±1.73, 0.45±1.54 and 0.66±1.6, respectively (p<0.001 for all). In multivariable models, a ≥2 line improvement in BCVA was independently associated with a 47% (β=0.20; CI 0.01 to 0.39) increase in Reading Scores, but was not independently associated with Mobility or Emotional Scores.
CONCLUSION: Nearly half of patients undergoing treatment for nAMD reported a 2-line improvement in vision which was, in turn, associated with substantial positive increases in Reading Scores. Improvements in Mobility and Emotional Scores appear to be driven by factors other than visual acuity. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  age-related macular degeneration; change; treatment; vision-related quality of life; visual acuity

Mesh:

Substances:

Year:  2017        PMID: 28659392     DOI: 10.1136/bjophthalmol-2017-310532

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  4 in total

1.  Calibrating the Impact of Vision Impairment (IVI): Creation of a Sample-Independent Visual Function Measure for Patient-Centered Outcomes Research.

Authors:  Judith E Goldstein; Eva Fenwick; Robert P Finger; Vijaya Gothwal; Mary Lou Jackson; Ecosse Lamoureux; Gwyneth Rees; Robert Massof
Journal:  Transl Vis Sci Technol       Date:  2018-12-28       Impact factor: 3.283

2.  Impact of visual impairment on physical activity in early and late age-related macular degeneration.

Authors:  Manuel Heinemann; Susanne G Welker; Jeany Q Li; Maximilian W M Wintergerst; Gabrielle N Turski; Christopher A Turski; Jan H Terheyden; Matthias M Mauschitz; Frank G Holz; Robert P Finger
Journal:  PLoS One       Date:  2019-10-21       Impact factor: 3.240

3.  A serum metabolomics study of patients with nAMD in response to anti-VEGF therapy.

Authors:  Yan Gao; Yi Chong Kelvin Teo; Roger W Beuerman; Tien Yin Wong; Lei Zhou; Chui Ming Gemmy Cheung
Journal:  Sci Rep       Date:  2020-01-28       Impact factor: 4.379

4.  Predictors of health-related quality of life in Chinese patients receiving treatment for neovascular age-related macular degeneration: a prospective longitudinal study.

Authors:  Wei Bian; Junli Wan; Mingqiong Tan; Jun Su; Yi Yuan; Zonghua Wang; Shiying Li
Journal:  BMC Ophthalmol       Date:  2020-07-16       Impact factor: 2.209

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.